Insider Trading Activity Anika Therapeutics Inc. (NASDAQ:ANIK) – CEO Sold 63,799 shares of Stock

ME Staff
-
0

Insider Trading Activity For Anika Therapeutics Inc. (NASDAQ:ANIK)

Charles H Sherwood , CEO of Anika Therapeutics Inc. (NASDAQ:ANIK) reportedly Sold 63,799 shares of the company’s stock at an average price of 50.79 for a total transaction amount of $3,240,351.21 SEC Form

Insider Trading History For Anika Therapeutics Inc. (NASDAQ:ANIK)

  • On 6/19/2013 Charles H Sherwood, CEO, sold 1,847 with an average share price of $18.00 per share and the total transaction amounting to $33,246.00.View SEC Filing
  • On 7/5/2013 Charles H Sherwood, CEO, sold 34,662 with an average share price of $18.01 per share and the total transaction amounting to $624,262.62.View SEC Filing
  • On 7/9/2013 Charles H Sherwood, CEO, sold 49,185 with an average share price of $18.06 per share and the total transaction amounting to $888,281.10.View SEC Filing
  • On 7/15/2013 Charles H Sherwood, CEO, sold 75,000 with an average share price of $20.11 per share and the total transaction amounting to $1,508,250.00.View SEC Filing
  • On 8/6/2013 Farmaceutici S.P.A. Fidia, Major Shareholder, sold 1,270,000 with an average share price of $24.52 per share and the total transaction amounting to $31,140,400.00.View SEC Filing
  • On 8/7/2013 Steve E Wheeler, Director, sold 11,016 with an average share price of $27.01 per share and the total transaction amounting to $297,542.16.View SEC Filing
  • On 8/8/2013 Steve E Wheeler, Director, sold 26,984 with an average share price of $23.61 per share and the total transaction amounting to $637,092.24.View SEC Filing

    • Analyst Ratings For Anika Therapeutics Inc. (NASDAQ:ANIK)
    These are No ratings tracked in the last 12 months. .
    The current consensus rating for Anika Therapeutics Inc. (NASDAQ:ANIK) is N/A (Score: NaN) with a consensus target price of N/A

    Analyst Ratings History For Anika Therapeutics Inc. (NASDAQ:ANIK)

    • On 8/27/2015 First Analysis Initiated Coverage of rating Equal to Equal Weight
    • On 2/26/2016 Barrington Research Boost Price Target of rating Outperform with a price target of $45.00 to $49.00
    • On 4/27/2016 Northland Securities Downgraded rating Outperform to Market Perform

    Recent Trading Activity for Anika Therapeutics Inc. (NASDAQ:ANIK)
    Shares of Anika Therapeutics Inc. closed the previous trading session at 51.16 up +0.89 1.77% with 119,924 shares trading hands.